Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Another therapeutic for COVID
View:
Comment by Pandora on Dec 23, 2020 6:19pm
Yes, collaborating with big money pharma again. In the meantime Cytodyn (CYDY) has done a trial on the mild to mid group and have just completed a blinded study on severe to critical patients (390) with results to be posted mid-January. No collaboration there even though it has possibly the best results of any therapeutic thus far -- but having to wait for numbers. They have also now started a ...more  
Comment by tdon1229 on Dec 23, 2020 6:56pm
  And when they realize that CCR5 is over expressed in the brains of stroke victims, maybe they'll get still another trial opportunity with leronlimab, which is a CCR5 agonist.
Comment by CancerSlayer on Dec 23, 2020 8:58pm
  Hi Tdon.  Just wanted to clarify Leronlimab is a CCR5 "antagonist", which is probably what you meant.  Controlling the exaggerated immune response or cytokine/chemokine storm will play a major role in treating the severely ill/hospitalized.  Theralase has a realistic opportunity to reduce hospitalizations in the future with its focus on an alternative/better ...more  
Comment by tdon1229 on Dec 24, 2020 7:46am
  Yes, CS, a "CCR5 antagonist" is what I meant to say ... my dancing fingertips skipped over a few letters and changed the meaning.  Thank you for pointing that out.   As for the potential for a universal treatment, from your lips to God's ear.  However, until Theralase gets some SP traction, or gains a partnership or three, progress towards that goal will be ...more  
Comment by Rumpl3StiltSkin on Dec 24, 2020 10:10am
Great discussion guys, Merry Christmas! I really hope that TLT can figure out how to roll out a Covid therapeutic that is simple to use in the clinics. We know 1433 is safe. We also know it should be effective. I also believe it can be used as a preventative? And it shouldn't matter too much what Covid 19 morphs into?
Comment by charlierock on Dec 24, 2020 11:49am
The potential for 1433 being applied to Covid and other viruses is very exciting. My major concerns are funding, research and clinical trials moving at glacier speed. Any kind of good news for this application would be icing on the cake. Let's hope 2021 brings the goods!
Comment by bartlman on Dec 24, 2020 3:08pm
Charlierock. I agree that 1433 being applied to Covid and other viruses is a very exciting notion. Now my understanding, based on what I read in the pr and newspaper article, was that they were about to begin an animal trial with 1433 being applied to the  the unsuspecting animals and hopefully not killing any of them. Supposing the animals are for the most part cured - dosing being the most ...more  
Comment by Pandora on Dec 23, 2020 11:28pm
I think it's the mother-in-law of one of the execs of CYDY is a stroke victim so they are very aware of it and it in their sights some place. Leronlimab Shows Early, but Promising Clinical Responses in First Two Patients Recovering from Stroke Download as PDF October 26, 2020 6:00am EDT VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250